DGX — Quest Diagnostics Balance Sheet
0.000.00%
- $21.19bn
- $26.66bn
- $9.87bn
- 95
- 54
- 82
- 92
Annual balance sheet for Quest Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1,158 | 872 | 315 | 686 | 549 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,523 | 1,438 | 1,195 | 1,210 | 1,304 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 3,058 | 2,741 | 1,898 | 2,372 | 2,392 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,231 | 2,304 | 2,351 | 2,418 | 2,764 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 14,026 | 13,611 | 12,837 | 14,022 | 16,153 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,776 | 1,753 | 1,551 | 1,815 | 2,169 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7,267 | 7,167 | 6,944 | 7,715 | 9,375 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 6,759 | 6,444 | 5,893 | 6,307 | 6,778 |
| Total Liabilities & Shareholders' Equity | 14,026 | 13,611 | 12,837 | 14,022 | 16,153 |
| Total Common Shares Outstanding |